|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||515.96 g·mol−1|
|3D model (JSmol)|
Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 (CB1) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects. It was discovered by Merck & Co.
In October 2008, Merck has stopped its phase III clinical trials with the drugs due to high level of central nervous system side effects, mainly depression and anxiety.